[Anticoagulation in atrial fibrillation. Instead of costly therapy control soon a tablet for all?].
D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000191:economics*; D001384:Azetidines / Q000191:economics* / Q000627:therapeutic use*; D001596:Benzylamines; D002986:Clinical Trials as Topic; D016903:Drug Monitoring / Q000191:economics*; D005343:Fibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D019934:International Normalized Ratio; D020766:Intracranial Embolism / Q000191:economics / Q000517:prevention & control*; D011355:Prodrugs / Q000191:economics* / Q000627:therapeutic use*; D016896:Treatment Outcome; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use
D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D011355:Prodrugs; C426686:ximelagatran; D014859:Warfarin